The global dementia treatment market accounted for USD 18.43 billion in 2023 and is expected to reach at USD 41.76 billion by 2034 with a CAGR of 7.72% during the forecast period 2024-2034. The market will grow as a result of factors such as the increasing prevalence of dementia, rising awareness and diagnosis rates, a lack of effective treatment options and unmet medical needs, government funding and support, and technological advancements.
The single biggest risk factor for dementia is becoming older, and the world's population is getting older quickly. The World Health Organization estimates that 55 million individuals worldwide suffer from dementia, and that number is projected to increase to 78 million in 2030 and 139 million in 2050. The need for dementia medicines is mostly being driven by this increasing disease load. For instance, Biogen Inc. reported favorable Phase 3 findings in March 2024 for Lecanemab, an experimental anti-amyloid beta antibody being used to treat Alzheimer's disease.
By indication, the Alzheimer’s disease dementia segment accounted for the highest revenue-grossing segment in the global dementia treatment market in 2023 owing to the increasing prevalence of Alzheimer's disease worldwide and the absence of a definitive cure, driving demand for symptom management drugs and supportive care services. For instance, in February 2024, Eli Lilly and Company presented data on their Donanemab medication at a significant Alzheimer's conference, demonstrating encouraging outcomes in delaying cognitive deterioration for patients with early Alzheimer's. Additionally, the Lewy body dementia (LBD) segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of Lewy body dementia as a distinct and prevalent form of dementia, leading to increased research efforts, improved diagnostic methods, and development of targeted treatment options.
By drug class, the cholinesterase inhibitors segment accounted for the highest revenue-grossing segment in the global dementia treatment market in 2023 owing to the effectiveness of cholinesterase inhibitors in managing cognitive symptoms associated with dementia, such as Alzheimer's disease, and their widespread use as a first-line pharmacological treatment option. For instance, Johnson & Johnson and a biotech firm collaborated to research innovative medicines that target particular genetic abnormalities associated with Alzheimer's disease in January 2024. Additionally, the NMDA receptor antagonists (memantine) segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of memantine's efficacy in managing moderate to severe Alzheimer's disease symptoms, alongside its favorable safety profile, driving adoption as an adjunctive therapy and potential for expanded indications.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global dementia treatment market in 2023 owing to the convenience, ease of administration, and patient preference for oral medications, leading to widespread adoption of oral formulations for dementia treatment. For instance, AbbVie Inc. received FDA clearance in December 2023 for its Alzheimer's disease medication Aduhelm (aducanumab), making it the first new drug approved in this category in a number of years. Additionally, the transdermal patch segment is predicted to grow at the fastest CAGR during the forecast period owing to the convenience, improved compliance, and steady drug delivery offered by transdermal patches, addressing challenges associated with oral administration and driving demand for this alternative delivery method.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global dementia treatment market in 2023 owing to the increasing prevalence of dementia-related hospitalizations and the availability of a wide range of dementia medications in hospital pharmacies, catering to the immediate needs of patients and healthcare providers. For instance, Eisai Co., Ltd. partnered with another pharmaceutical business in October 2023 to co-develop and co-commercialize Lecanemab (marketed by Biogen as Leqembi), subject to regulatory approval. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the convenience, accessibility, and expanding e-commerce platforms facilitating easier access to dementia medications and related products, driving the growth of online pharmacies in the market.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of dementia, advanced healthcare infrastructure, favorable reimbursement policies, and increasing research and development activities in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly aging population, increasing awareness about dementia, improving healthcare infrastructure, and rising investments in healthcare across the Asia Pacific region. For instance, Boehringer Ingelheim International GmbH announced in March 2023 that it will be working with a university research group to investigate the possibility of using artificial intelligence for dementia therapy and diagnosis early.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
The single biggest risk factor for dementia is becoming older, and the world's population is getting older quickly. The World Health Organization estimates that 55 million individuals worldwide suffer from dementia, and that number is projected to increase to 78 million in 2030 and 139 million in 2050. The need for dementia medicines is mostly being driven by this increasing disease load. For instance, Biogen Inc. reported favorable Phase 3 findings in March 2024 for Lecanemab, an experimental anti-amyloid beta antibody being used to treat Alzheimer's disease.
By indication, the Alzheimer’s disease dementia segment accounted for the highest revenue-grossing segment in the global dementia treatment market in 2023 owing to the increasing prevalence of Alzheimer's disease worldwide and the absence of a definitive cure, driving demand for symptom management drugs and supportive care services. For instance, in February 2024, Eli Lilly and Company presented data on their Donanemab medication at a significant Alzheimer's conference, demonstrating encouraging outcomes in delaying cognitive deterioration for patients with early Alzheimer's. Additionally, the Lewy body dementia (LBD) segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of Lewy body dementia as a distinct and prevalent form of dementia, leading to increased research efforts, improved diagnostic methods, and development of targeted treatment options.
By drug class, the cholinesterase inhibitors segment accounted for the highest revenue-grossing segment in the global dementia treatment market in 2023 owing to the effectiveness of cholinesterase inhibitors in managing cognitive symptoms associated with dementia, such as Alzheimer's disease, and their widespread use as a first-line pharmacological treatment option. For instance, Johnson & Johnson and a biotech firm collaborated to research innovative medicines that target particular genetic abnormalities associated with Alzheimer's disease in January 2024. Additionally, the NMDA receptor antagonists (memantine) segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of memantine's efficacy in managing moderate to severe Alzheimer's disease symptoms, alongside its favorable safety profile, driving adoption as an adjunctive therapy and potential for expanded indications.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global dementia treatment market in 2023 owing to the convenience, ease of administration, and patient preference for oral medications, leading to widespread adoption of oral formulations for dementia treatment. For instance, AbbVie Inc. received FDA clearance in December 2023 for its Alzheimer's disease medication Aduhelm (aducanumab), making it the first new drug approved in this category in a number of years. Additionally, the transdermal patch segment is predicted to grow at the fastest CAGR during the forecast period owing to the convenience, improved compliance, and steady drug delivery offered by transdermal patches, addressing challenges associated with oral administration and driving demand for this alternative delivery method.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global dementia treatment market in 2023 owing to the increasing prevalence of dementia-related hospitalizations and the availability of a wide range of dementia medications in hospital pharmacies, catering to the immediate needs of patients and healthcare providers. For instance, Eisai Co., Ltd. partnered with another pharmaceutical business in October 2023 to co-develop and co-commercialize Lecanemab (marketed by Biogen as Leqembi), subject to regulatory approval. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the convenience, accessibility, and expanding e-commerce platforms facilitating easier access to dementia medications and related products, driving the growth of online pharmacies in the market.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high prevalence of dementia, advanced healthcare infrastructure, favorable reimbursement policies, and increasing research and development activities in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly aging population, increasing awareness about dementia, improving healthcare infrastructure, and rising investments in healthcare across the Asia Pacific region. For instance, Boehringer Ingelheim International GmbH announced in March 2023 that it will be working with a university research group to investigate the possibility of using artificial intelligence for dementia therapy and diagnosis early.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Indication, Drug Class, Route of Administration, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Dementia Treatment Market Report 2023 - 2034
Dementia Treatment Market Analysis & Forecast by Indication 2023 - 2034 (Revenue USD Bn)
- Alzheimer’s Disease Dementia
- Vascular Dementia
- Lewy Body Dementia
- Frontotemporal Dementia (FTD)
- Parkinson's Disease Dementia
- Others
Dementia Treatment Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Cholinesterase Inhibitors
- NMDA Receptor Antagonist
- MAO Inhibitors
- Combination Drug
- Others
Dementia Treatment Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Oral
- Transdermal Patch
- Injectable
Dementia Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Dementia Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Dementia Treatment Market: Indication Estimates & Trend Analysis
8. Dementia Treatment Market: Drug Class Estimates & Trend Analysis
9. Dementia Treatment Market: Route of Administration Estimates & Trend Analysis
10. Dementia Treatment Market: Distribution Channel Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Dementia Treatment Market
13. Europe Global Dementia Treatment Market
14. Asia Pacific Global Dementia Treatment Market
15. Latin America Global Dementia Treatment Market
16. MEA Global Dementia Treatment Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Biogen Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Novartis AG
- Merck & Co. Inc.
- Johnson & Johnson
- AstraZeneca PLC
- Teva Pharmaceutical Industries Ltd.
- Roche Holding AG
- AbbVie Inc.
- Lundbeck
- Eisai Co. Ltd.. UCB S.A.
- Boehringer Ingelheim International GmbH
- Allergan plc.
